Explore the Effect of Gynostemma Pentaphyllum on Patients With Metabolic Syndrome

Inclusion Criteria:

• Low-density lipoprotein (LDL) cholesterol ≥130 mg/dL (3.4 mmol/L ), or conforms to thediagnosis criteria for metabolic syndrome (based on the MetS diagnostic criteriadeveloped by IDF and AHA in 2009), that is, having three or more of the followingtraits:

1. waist circumference ≥90 cm in men or ≥80 cm in women;
2. Elevated TG (drug treatment for elevated TG is an alternate indicator) ≥150 mg/dL (1.7 mmol/L);
3. Reduced HDL-c (drug treatment for reduced HDL-c is an alternate indicator) < 40mg/dL (1.03 mmol/L) in males < 50 mg/dL (1.29 mmol/L) in females;
4. Elevated blood pressure (anti-hypertensive drug treatment in a patient with ahistory of hypertension is an alternate indicator). Systolic ≥ 130 and/ordiastolic ≥ 85 mmHg;
5. Elevated fasting glucose (drug treatment for elevated glucose is an alternateindicator) ≥ 100 mg/dL (5.6 mmol/L).

• Be over 18 years old or younger than 80 years old, no gender limit.
• Have a good follow-up compliance and can be followed up for more than 3 months;
• From 2 weeks before enrollment to the end of the entire trial, the treatment regimenwill not change.

Exclusion Criteria:

• Pregnant and lactating women;
• Allergic or toxic reactions to gynostemma and other drugs;
• Infectious diseases such as viral hepatitis, AIDS, syphilis, tuberculosis are active;
• After drug treatment, still showing high blood sugar (fasting blood glucose higherthan 200mg/dL, 11.1mmol/L) or hyperlipidemia, or hypertension (higher than 180/110mmHg);
• Any conditions judged by the investigator that affect enrollment.